Sai Parenterals Limited (NSE: SAIPARENT) has completed the acquisition of a 60% equity stake in Prathyak Laboratories Private Limited for Rs. 15 crore, funded from the unutilised net proceeds of the Company’s initial public offering. This acquisition replaces the greenfield research centre the Company had originally intended to build. Prathyak Laboratories, now renamed as Sai Prathyak Laboratories Private Limited, has been in operation for three years and brings 28 research scientists and a development pipeline of 150 SKUs across 86 molecules. The acquisition provides Sai Parenterals with immediate access to a fully operational R&D facility, significantly accelerating its development work and reducing the time and effort required to assemble a scientific team.

Strategic Benefits of the Acquisition

The acquisition of an operating R&D platform rather than constructing one allows development work to begin immediately. It removes the construction cycle and, more significantly, the considerably harder task of assembling a scientific team of this calibre, which would have slowed the pace of a greenfield build. Prathyak’s development work supports the Company’s injectable programme directly. Formulations developed at this R&D centre can be taken into commercial production as the Company’s injectable capacity is expanded and upgraded, shortening the path from development to supply in regulated and semi-regulated markets.

Future Plans and Expansion

The residual 40% may be acquired through a Right of First Refusal (ROFR) at the same valuation as the present transaction, to be funded from internal accruals, taking Prathyak to a wholly owned position. Commenting on the acquisition, Mr. Anil Kumar Karusala, Chairman and Managing Director, Sai Parenterals Limited, said: ‘Building a research centre from the ground up would have cost us a construction cycle and, far more significantly, the time taken to assemble a scientific team. Prathyak gives us both on day one — 28 research scientists who have worked together for three years, and a pipeline of 150 SKUs across 86 molecules in exactly the complex injectable and oncology areas we are building towards. The value of this acquisition lies in what it enables elsewhere in the Group. Work already completed at this R&D centre can be taken into production as our injectable capacity is expanded. The same R&D team will also develop the new products we are required to launch each year under our Australian agreements. We have acquired 60% today and will move to full ownership at the same valuation. This is a further step in the growth plan we set out at the time of our listing: deeper integration across our own value chain, a faster route from development to commercial supply, and capability built inside the Group instead of with third parties. We will continue to pursue opportunities of this kind, organic and inorganic, that strengthen the platform and create lasting value for our stakeholders.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sai Parenterals Limited

Sai Parenterals Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Sai falls 15.3% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at 126.1% and profits at 111.8% CAGR. Both numbers are exceptional. The stock gains 0.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Both the business and the stock move in the right direction. Revenue grows at 126.1%, profits at 111.8%, and the PEG sits at 0.99 — below its growth rate. That combination is rare. Check Fundamentals of Sai Parenterals Limited.

Aurobindo Pharma Limited (NSE: AUROPHARMA) is pleased to announce the receipt of final approval from the US Food & Drug Administration (USFDA) to manufacture and market Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. These tablets are bioequivalent and therapeutically equivalent to the reference listed drug, Fycompa® Tablets, of Catalyst Pharmaceuticals, Inc. The product will be manufactured at Unit -IV of APL Healthcare, a wholly-owned subsidiary of the Company, and is set to launch in Q3FY27. The approved product has an estimated market size of US$ 67 million for the twelve months ending August 2026, according to IQVIA MAT.

Significance of Approval

This approval marks a significant milestone for Aurobindo Pharma as it expands its portfolio of CNS products. Perampanel Tablets are indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 4 years and older and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older.

Company’s Growth and Future Prospects

With this approval, Aurobindo Pharma now has a total of 599 ANDA approvals from USFDA. The company continues to strengthen its position in the global pharmaceutical market with its robust product portfolio spread over seven major therapeutic areas. Aurobindo Pharma’s commitment to innovation and quality is evident in its extensive list of manufacturing and packaging facilities approved by leading regulatory agencies worldwide.

Aurobindo Pharma Limited remains dedicated to its mission of delivering high-quality, affordable medications to patients globally. With the launch of Perampanel Tablets, the company is poised to further its growth and contribute to improved patient outcomes in the epilepsy treatment landscape.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Aurobindo Pharma Limited

Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Aurobindo posts a 3.5% three-month gain, but softens in the last few weeks. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gives back 0.4% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Both the business and the stock move in the right direction. Revenue grows at 10.7%, profits at 22.1%, and the PEG sits at 1.17 — below its growth rate. That combination is rare. Check Fundamentals of Aurobindo Pharma Limited.

Sun Pharmaceutical Industries Limited (SUNPHARMA) announced today that LEQSELVI® (deuruxolitinib) will be featured in seven presentations at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, including a featured oral presentation reporting long-term safety results from a European open-label extension (OLE) study evaluating up to two years of treatment in adults with severe alopecia areata (AA). The featured oral presentation found that the safety profile of LEQSELVI remained consistent with previous clinical experience through up to two years of open-label treatment in adults with severe AA.

Long-Term Efficacy and Safety

Most treatment-emergent adverse events were mild or moderate in severity, treatment discontinuations due to adverse events were uncommon, and no deaths, thrombosis, or major adverse cardiovascular events were reported among patients receiving the FDA-approved dose of 8 mg twice-daily. Long-term efficacy analyses presented in a poster also showed durable scalp hair regrowth through Week 108 in patients receiving LEQSELVI in the European OLE. Of OLE baseline treatment responders maintaining response at Week 52 and continuing in the study, 93.9% maintained response at Week 108. Many patients (76.6%) who were baseline nonresponders achieved response by Week 52.

Clinical Significance

“Severe alopecia areata is a chronic autoimmune disease, making long-term treatment considerations particularly important for both patients and their clinicians,” said Arash Mostaghimi, MD, MPA, MPH, FAAD, Vice Chair of Clinical Trials and Innovation and Associate Professor of Dermatology at Brigham and Women’s Hospital. “Collectively, these data show durable efficacy and maintenance of response for deuruxolitinib over time and reinforce the growing body of evidence supporting its use as a long-term treatment option for eligible adults.”

The LEQSELVI data presentation is one of 22 presentations from Sun Pharma across its dermatology and immunology portfolio. LEQSELVI® (deuruxolitinib) 8 mg tablets is an oral selective inhibitor of Janus kinases JAK1 and JAK2 FDA-approved for the treatment of adults with severe alopecia areata.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Sun moves sideways over three months, with neither buyers nor sellers taking control. The PEG reaches 3.38. The stock trades on brand and index weight, not on growth. Premium net margins of 20.2% demonstrate strong cost discipline and a wide competitive moat. The stock holds at 47% of its 52-week range with RSI at 37. In other words, neither side has a clear edge right now. Revenue grows at 10.4% and profits at 10.6% CAGR, with D/E of 0.03. Meanwhile, the stock dips 5.5% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sun Pharmaceutical Industries Limited.